News

Chinese speeds approval process of biotech products as part of trade deal

China has agreed to accelerate the process for approving U.S. biotechnology products as part the trade deal announced by the Trump Administration.

Chinese government officials are expected meet later this month to review eight pending biotechnology products, and if not approved, have agreed to provide reasons and information necessary to move the process along.

The Biotechnology Innovation Organization says the 100-Day Action plan between the U.S. and China is the first step toward improved relationships.

In a statement released after the announcement, Executive Vice President for International Affairs Joseph Damond said the test of success for the agreement will be for China to review and approve pending products, and establish a more streamlined process for registrations.

The Biotechnology Innovation Organization is one of the largest biotechnology trade associations in the world and represents companies in more than 30 countries including Monsanto.